Vascular Biogenics (VBLT) Stock Price, News & Analysis

Company Overview

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.16 to $5.46
• 52-Week Range: N/A
• Volume: 161,505 shs
• Average Volume: 2.19 million shs
• Market Capitalization: $423.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VBLT Stock Analysis - Frequently Asked Questions

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) released its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company earned $0.20 million during the quarter, compared to analyst estimates of $0.20 million.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vascular Biogenics investors own include T2 Biosystems (TTOO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), OPKO Health (OPK), VBI Vaccines (VBIV), TherapeuticsMD (TXMD) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 4/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VBLT
• Previous Symbol: NASDAQ:VBLX
• CIK: 1603207
• Web: www.vblrx.com
• Phone: (728) 993-5000
• Fax: 972-8993-5001
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-32,300,000.00
• Net Margins: N/A
• Pretax Margin: -3,317.05%
• Return on Equity: -73.45%
• Return on Assets: -54.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.63
• Quick Ratio: 4.63

Sales & Book Value

• Annual Sales: $660,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.32 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 77,640,000
• Free Float: 72,881,000
• Market Cap: $423.91 million
• Optionable: Optionable
• Beta: 0.77